About Dr. Neal G. Copeland
Neal Copeland received his Ph.D. in Biochemistry from the University of Utah. Following postdoctoral studies at Harvard Medical School, he joined the staff of The Jackson Laboratory and then the National Cancer Institute-Frederick, where he was Director of the Mammalian Genetics Laboratory, the forerunner of the Mouse Cancer Genetics Program that he also directed. He moved to the Institute of Molecular and Cell Biology in Singapore in 2006, where he served as the Executive Director for most of his stay. In 2011 he returned to the U.S. to serve as Director of the Cancer Biology Program at Houston Methodist Research Institute. For more than 35 years he co-headed a laboratory with Nancy Jenkins, successfully modeling many different types of human disease in the mouse but focusing exclusively on cancer the last 11 years. They have co-authored more than 800 papers and are among the most cited biomedical research scientists in the world today. Copeland has served on numerous scientific advisory and editorial boards and has consulted for several biotechnology and pharmaceutical companies. Dr. Copeland is also a member of the US National Academy of Sciences. In 2017, Jenkins and Copeland closed their lab and moved to the Department of Genetics at the MD Anderson Cancer Center.
AREAS OF EXPERTISE Mouse models of cancer/ Insertional mutagenesis/ Forward genetic screens/ High throughput sequencing/ Candidate cancer gene detection
Read about Dr. Copeland in Cancerwise
Professor of Practice, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
|1976||The University of Utah, Salt Lake City, UT, USA, PHD, Biochemistry|
|1971||The University of Utah, Salt Lake City, UT, USA, BS, Biology|
|1976-1980||Postdoctoral Fellow, Viral Oncology, Dana Farber Cancer Institute, Boston, MA|
|2020||Prince Hitachi Prize for Comparative Oncology|
|2011||Academy of Medicine, Engineering and Science of Texas|
|2009||National Academy of Sciences|
- Aiderus A, Contreras-Sandoval AM, Meshey AL, Newberg JY, Ward JM, Swing DA, Copeland NG, Jenkins NA, Mann KM, Mann MB. Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation. Cancers (Basel) 13(2), 2021. e-Pub 2021. PMID: 33435458.
- Takeda H, Kataoka S, Nakayama M, Ali MAE, Oshima H, Yamamoto D, Park JW, Takegami Y, An T, Jenkins NA, Copeland NG, Oshima M. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc Natl Acad Sci U S A 116(31):15635-15644, 2019. e-Pub 2019. PMID: 31300537.
- Levine AJ, Jenkins NA, Copeland NG. The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters. Cancer Cell 35(1):10-15, 2019. PMID: 30645969.
- Mann KM, Newberg JY, Black MA, Jones DJ, Amaya-Manzanares F, Guzman-Rojas L, Kodama T, Ward JM, Rust AG, van der Weyden L, Yew CC, Waters JL, Leung ML, Rogers K, Rogers SM, McNoe LA, Selvanesan L, Navin N, Jenkins NA, Copeland NG, Mann MB. Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq. Nat Biotechnol 34(9):962-72, 2016. e-Pub 2016. PMID: 27479497.
- Kodama T, Bard-Chapeau EA, Newberg JY, Kodama M, Rangel R, Yoshihara K, Ward JM, Jenkins NA, Copeland NG. Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma. Gastroenterology 151(2):324-337.e12, 2016. e-Pub 2016. PMID: 27178121.
- Kodama T, Newberg JY, Kodama M, Rangel R, Yoshihara K, Tien JC, Parsons PH, Wu H, Finegold MJ, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proc Natl Acad Sci U S A 113(24):E3384-93, 2016. e-Pub 2016. PMID: 27247392.
- Mann MB, Black MA, Jones DJ, Ward JM, Yew CC, Newberg JY, Dupuy AJ, Rust AG, Bosenberg MW, McMahon M, Print CG, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma. Nat Genet 47(5):486-95, 2015. e-Pub 2015. PMID: 25848750.
- Takeda H, Wei Z, Koso H, Rust AG, Yew CC, Mann MB, Ward JM, Adams DJ, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet 47(2):142-50, 2015. e-Pub 2015. PMID: 25559195.
- Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet 46(1):24-32, 2014. e-Pub 2013. PMID: 24316982.
- Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436(7048):221-6, 2005. PMID: 16015321.
- Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33(4):e36, 2005. e-Pub 2005. PMID: 15731329.
- Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res 13(3):476-84, 2003. PMID: 12618378.
- Copeland NG, Jenkins NA, Court DL. Recombineering: a powerful new tool for mouse functional genomics. Nat Rev Genet 2(10):769-79, 2001. PMID: 11584293.
- Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T, Shaughnessy JD, Jenkins NA, Copeland NG. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet 23(3):348-53, 1999. PMID: 10610183.
- Fletcher CF, Lutz CM, O'Sullivan TN, Shaughnessy JD, Hawkes R, Frankel WN, Copeland NG, Jenkins NA. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87(4):607-17, 1996. PMID: 8929530.
- Copeland NG, Jenkins NA, Gilbert DJ, Eppig JT, Maltais LJ, Miller JC, Dietrich WF, Weaver A, Lincoln SE, Steen RG. A genetic linkage map of the mouse: current applications and future prospects. Science 262(5130):57-66, 1993. PMID: 8211130.
- Copeland NG, Gilbert DJ, Jenkins NA, Nadeau JH, Eppig JT, Maltais LJ, Miller JC, Dietrich WF, Steen RG, Lincoln SE. Genome maps IV 1993. Wall chart. Science 262(5130):67-82, 1993. PMID: 8211131.
- Hodgkinson CA, Moore KJ, Nakayama A, Steingrímsson E, Copeland NG, Jenkins NA, Arnheiter H. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74(2):395-404, 1993. PMID: 8343963.
- Kingsley DM, Bland AE, Grubber JM, Marker PC, Russell LB, Copeland NG, Jenkins NA. The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF beta superfamily. Cell 71(3):399-410, 1992. PMID: 1339316.
- Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356(6367):314-7, 1992. PMID: 1372394.
- Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63(1):175-83, 1990. PMID: 1698554.
- Buchberg AM, Cleveland LS, Jenkins NA, Copeland NG. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 347(6290):291-4, 1990. PMID: 2169593.
- Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54(6):831-40, 1988. PMID: 2842066.
- Takeda H, Jenkins NA, Copeland NG. Identification of cancer driver genes using Sleeping Beauty transposon mutagenesis. Cancer Sci. e-Pub 2021. PMID: 33783919.
- Nakae A, Kodama M, Okamoto T, Tokunaga M, Shimura H, Hashimoto K, Sawada K, Kodama T, Copeland NG, Jenkins NA, Kimura T. Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. Biochem Biophys Res Commun 552:120-127. e-Pub 2021. PMID: 33744759.
- Gudmundsson KO, Nguyen N, Oakley K, Han Y, Gudmundsdottir B, Liu P, Tessarollo L, Jenkins NA, Copeland NG, Du Y. Prdm16 is a critical regulator of adult long-term hematopoietic stem cell quiescence. Proc Natl Acad Sci U S A. e-Pub 2020. PMID: 33268499.